Please login to the form below

Not currently logged in
Email:
Password:

Brilinta

This page shows the latest Brilinta news and features for those working in and with pharma, biotech and healthcare.

AZ expects return to growth this year after 2017 decline

AZ expects return to growth this year after 2017 decline

The contribution of these drugs as well as blockbuster sales for antiplatelet therapy Brilinta (ticagrelor) and diabetes drug Farxiga (dapagliflozin) allowed AZ to boost operating profit by 2% to $6.86bn

Latest news

  • AZ CEO says company’s renaissance is on track AZ CEO says company’s renaissance is on track

    Lynparza sales rose 40% to $81m in the quarter. Other pillars of the CEO’s plans for AZ delivered as hoped, with antiplatelet drug Brilinta (ticagrelor) rising 37% to $284m, although

  • Another failed trial knocks back AZ's plan to grow Brilinta Another failed trial knocks back AZ's plan to grow Brilinta

    AstraZeneca's hopes of expanding the uses of its antiplatelet drug Brilinta have taken another knock. ... Its failure comes after Brilinta was unable to show a benefit on outcomes in ischaemic stroke in the SOCRATES trial.

  • NICE backs use of AZ's Brilique as maintenance therapy NICE backs use of AZ's Brilique as maintenance therapy

    The value of longer-term use in heart attack patients was revealed in the PEGASUS trial, which showed Brilinta plus low-dose aspirin was significantly more effective than placebo plus aspirin ... The positive verdict is a boost for AZ, as Brilique (known

  • AZ feels Crestor sting but new products provide some relief AZ feels Crestor sting but new products provide some relief

    The downturn was in line with expectations, however, and investors took solace from encouraging results for AZ's growth platforms, including new cancer drugs and resurgent antiplatelet drug Brilinta (ticagrelor). ... There were gains across the board for

  • AZ's Brilinta disappoints in stroke trial AZ's Brilinta disappoints in stroke trial

    AZ's Brilinta disappoints in stroke trial. Antiplatelet drug fails to demonstrate significant benefit in ischaemic stroke. ... of cardiovascular events - in the hope they will allow the indications for Brilinta to be extended.

More from news
Approximately 9 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics